PLX vs. ALVR, CRIS, ATRA, GRTS, CVM, CGTX, ATHA, PASG, BLUE, and VIGL
Should you be buying Protalix BioTherapeutics stock or one of its competitors? The main competitors of Protalix BioTherapeutics include AlloVir (ALVR), Curis (CRIS), Atara Biotherapeutics (ATRA), Gritstone bio (GRTS), CEL-SCI (CVM), Cognition Therapeutics (CGTX), Athira Pharma (ATHA), Passage Bio (PASG), bluebird bio (BLUE), and Vigil Neuroscience (VIGL). These companies are all part of the "biological products, except diagnostic" industry.
Protalix BioTherapeutics (NYSE:PLX) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, analyst recommendations, community ranking, earnings, dividends and profitability.
Protalix BioTherapeutics has a beta of 0.88, meaning that its stock price is 12% less volatile than the S&P 500. Comparatively, AlloVir has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500.
Protalix BioTherapeutics has a net margin of 12.69% compared to AlloVir's net margin of 0.00%. Protalix BioTherapeutics' return on equity of 29.73% beat AlloVir's return on equity.
AlloVir received 22 more outperform votes than Protalix BioTherapeutics when rated by MarketBeat users. However, 62.50% of users gave Protalix BioTherapeutics an outperform vote while only 57.45% of users gave AlloVir an outperform vote.
Protalix BioTherapeutics currently has a consensus price target of $10.00, suggesting a potential upside of 769.57%. AlloVir has a consensus price target of $18.50, suggesting a potential upside of 2,220.91%. Given AlloVir's higher probable upside, analysts plainly believe AlloVir is more favorable than Protalix BioTherapeutics.
In the previous week, AlloVir had 7 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 8 mentions for AlloVir and 1 mentions for Protalix BioTherapeutics. Protalix BioTherapeutics' average media sentiment score of 0.00 beat AlloVir's score of -0.80 indicating that Protalix BioTherapeutics is being referred to more favorably in the media.
Protalix BioTherapeutics has higher revenue and earnings than AlloVir. AlloVir is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.
16.5% of Protalix BioTherapeutics shares are held by institutional investors. Comparatively, 66.1% of AlloVir shares are held by institutional investors. 5.0% of Protalix BioTherapeutics shares are held by insiders. Comparatively, 40.0% of AlloVir shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Protalix BioTherapeutics beats AlloVir on 11 of the 16 factors compared between the two stocks.
Get Protalix BioTherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for PLX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Protalix BioTherapeutics Competitors List
Related Companies and Tools
